Comparative proteomic analysis of endothelial cells progenitor cells derived from cord blood- and peripheral blood for cell therapy

Kim, Jumi; Jeon, Young‐Joo; Kim, Hye-Eun; Shin, Jae‐Eun; Chung, Hyung Min; Chae, Jung‐Il

doi:10.1016/j.biomaterials.2012.11.017

Cited by 15 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High specificity of the cell isolation technique in combination with advanced sample procurement and preparation and ultrasensitive PLOT-nLC-MS enabled differential profiling of limited levels of model samples and isolates collected from donors. Furthermore, we reduced the amount of blood necessary to conduct deep proteomic analysis of EPCs and HSCs by at least 1-2 orders of magnitude in comparison to other reported methods (27,28). These results show the clear potential for in-depth discovery proteomic characterization of circulating Synthetic stable isotope labeled peptides spiked in as internal standards.…”

Section: Proteomic Profiling Of Hematopoietic Stem Cells (Hscs) and Ementioning

confidence: 68%

“…1B). A key attribute of this platform is the reduction of the minimum amount of blood necessary to study EPC and HSC and potentially other rare cell populations by at least 1-2 orders of magnitude relative to the current state of the art (27,28). We first detail the individual steps that lead to the advanced workflow for deep proteomic analysis of rare cells in whole blood.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood*

Plouffe

Belov

et al. 2015

Molecular & Cellular Proteomics

148

173

View full text Add to dashboard Cite

Section: Proteomic Profiling Of Hematopoietic Stem Cells (Hscs) and Ementioning

confidence: 68%

Section: Resultsmentioning

confidence: 99%

An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood*

Plouffe

Belov

et al. 2015

Molecular & Cellular Proteomics

148

173

View full text Add to dashboard Cite

“…High antioxidant activity has also been suggested for endothelial progenitor cells [65], and large contents of peroxide detoxifying enzymes were demonstrated at the blood-brain barrier long ago [66]. …”

Section: Discussionmentioning

confidence: 99%

The Antioxidant Machinery of Young and Senescent Human Umbilical Vein Endothelial Cells and Their Microvesicles

Bodega

Alique

Bohórquez

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

We examine the antioxidant role of young and senescent human umbilical vein endothelial cells (HUVECs) and their microvesicles (MVs). Proteomic and Western blot studies have shown young HUVECs to have a complete and well-developed antioxidant system. Their MVs also contain antioxidant molecules, though of a smaller and more specific range, specialized in the degradation of hydrogen peroxide and the superoxide anion via the thioredoxin-peroxiredoxin system. Senescence was shown to be associated with a large increase in the size of the antioxidant machinery in both HUVECs and their MVs. These responses might help HUVECs and their MVs deal with the more oxidising conditions found in older cells. Functional analysis confirmed the antioxidant machinery of the MVs to be active and to increase in size with senescence. No glutathione or nonpeptide antioxidant (ascorbic acid and vitamin E) activity was detected in the MVs. Endothelial cells and MVs seem to adapt to higher ROS concentrations in senescence by increasing their antioxidant machinery, although this is not enough to recover completely from the senescence-induced ROS increase. Moreover, MVs could be involved in the regulation of the blood plasma redox status by functioning as ROS scavengers.

show abstract

“…Due to the higher cell frequency (20) and the stronger cell proliferative ability (19,21), human UCB has been defined as a more ideal source of EPCs. UCB-EPCs have been a focus of regenerative treatment for ischemic diseases, and a number of studies have examined their application in ischemic diseases in various animal models; however, some researchers have used EPCs at ununiformed passages, such as passage 2–5 (37), passage 3–4 (29), passage 5 (38), or in some case, have not stated the specific cell passage used (39,40). Thus, further supportive evidence for cell passage selection in ischemic treatment is still needed.…”

Section: Discussionmentioning

confidence: 99%

Decreased phosphorylation of PDGFR-β impairs the angiogenic potential of expanded endothelial progenitor cells via the inhibition of PI3K/Akt signaling

Mei

Wang

et al. 2017

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract.Human umbilical cord blood-derived endothelial progenitor cells (EPCs) have been proven to contribute to postnatal angiogenesis, and have been applied in various models of ischemia. However, to date, to the best of our knowledge, there is no available data on the angiogenic properties of EPCs during the process of in vitro expansion. In this study, we expanded EPCs to obtain cells at different passages, and analyzed their cellular properties and angiogenic ability. In the process of expansion, no changes were observed in cell cobblestone-like morphology, apoptotic rate and telomere length. However, the cell proliferative ability was significantly decreased. Additionally, the expression of CD144, CD90 and KDR was significantly downregulated in the later-passage cells. Vascular formation assay in vitro revealed that EPCs at passage 4 and 6 formed more integrated and organized capillary-like networks. In a murine model of hind limb ischemia, the transplantation of EPCs at passage 4 and 6 more effectively promoted perfusion recovery in the limbs on days 7 and 14, and promoted limb salvage and histological recovery. Furthermore, the phosphorylation levels of platelet-derived growth factor receptor-β (PDGFR-β) were found to be significantly decreased with the in vitro expansion process, accompanied by the decreased activation of the PI3K/Akt signaling pathway. When PDGFR inhibitor was used to treat the EPCs, the differences in the angiogenic potential and migratory ability among the EPCs at different passages were no longer observed; no significant differences were also observed in the levels of phosphorylated PI3K/Akt between the EPCs at different passages following treatment with the inhibitor. On the whole, our findings indicate that the levels of phosphorylated PDGFR-β are decreased in EPCs with the in vitro expansion process, which impairs their angiogenic potential by inhibiting PI3K/Akt signaling. Our findings may aid in the more effective selection of EPCs of different passages for the clinical therapy of ischemic disease.

show abstract

Comparative proteomic analysis of endothelial cells progenitor cells derived from cord blood- and peripheral blood for cell therapy

Cited by 15 publications

References 54 publications

An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood*

An Integrated Platform for Isolation, Processing, and Mass Spectrometry-based Proteomic Profiling of Rare Cells in Whole Blood*

The Antioxidant Machinery of Young and Senescent Human Umbilical Vein Endothelial Cells and Their Microvesicles

Decreased phosphorylation of PDGFR-β impairs the angiogenic potential of expanded endothelial progenitor cells via the inhibition of PI3K/Akt signaling

Contact Info

Product

Resources

About